PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.28%
Revenue growth under 50% of ADI's 5.79%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.54%
Gross profit growth under 50% of ADI's 7.22%. Michael Burry would be concerned about a severe competitive disadvantage.
10.98%
EBIT growth 50-75% of ADI's 18.61%. Martin Whitman would suspect suboptimal resource allocation.
10.98%
Operating income growth at 50-75% of ADI's 18.61%. Martin Whitman would doubt the firm’s ability to compete efficiently.
27.66%
Net income growth above 1.5x ADI's 10.79%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.00%
EPS growth above 1.5x ADI's 9.76%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
28.00%
Diluted EPS growth above 1.5x ADI's 10.26%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-1.93%
Share reduction while ADI is at 0.61%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.28%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.79%
Dividend reduction while ADI stands at 49.75%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
86.17%
Positive OCF growth while ADI is negative. John Neff would see this as a clear operational advantage vs. the competitor.
308.00%
Positive FCF growth while ADI is negative. John Neff would see a strong competitive edge in net cash generation.
7.93%
10Y revenue/share CAGR under 50% of ADI's 33.08%. Michael Burry would suspect a lasting competitive disadvantage.
32.39%
5Y revenue/share CAGR under 50% of ADI's 73.55%. Michael Burry would suspect a significant competitive gap or product weakness.
69.82%
3Y revenue/share CAGR above 1.5x ADI's 42.59%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
102.84%
10Y OCF/share CAGR above 1.5x ADI's 66.06%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
72.68%
5Y OCF/share CAGR above 1.5x ADI's 26.67%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
172.49%
Positive 3Y OCF/share CAGR while ADI is negative. John Neff might see a big short-term edge in operational efficiency.
158.75%
Net income/share CAGR at 50-75% of ADI's 213.43%. Martin Whitman might question if the firm’s product or cost base lags behind.
36.06%
Below 50% of ADI's 183.57%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
564.91%
3Y net income/share CAGR above 1.5x ADI's 310.04%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
285.05%
10Y equity/share CAGR above 1.5x ADI's 178.10%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
58.13%
Below 50% of ADI's 127.92%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.89%
Below 50% of ADI's 33.10%. Michael Burry suspects a serious short-term disadvantage in building book value.
39.88%
Dividend/share CAGR of 39.88% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
5.99%
Dividend/share CAGR of 5.99% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-6.00%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
1.81%
AR growth is negative/stable vs. ADI's 8.10%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
5.53%
Inventory growth well above ADI's 5.76%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
0.54%
Asset growth well under 50% of ADI's 4.29%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.72%
1.25-1.5x ADI's 4.41%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-51.52%
We’re deleveraging while ADI stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-6.03%
Our R&D shrinks while ADI invests at 3.95%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.93%
We cut SG&A while ADI invests at 4.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.